Skip to main content
. 2016 Mar 22;14(1):1–20. doi: 10.1016/j.ejcsup.2016.01.001

Table 15.

Planned interim analysis grade ≥III AEs safety results [96].

Docetaxel (N = 44) Docetaxel + ramucirumab (N = 46)
Haematological toxicities
Neutropenia 36 28
Febrile neutropenia 11 20
Anaemia 5 9
Thrombocytopenia 0 7
Non-haematological toxicities
Fatigue 11 33
Pneumonia 9 13
Sepsis 7 9
Stomatitis 0 7
Diarrhoea 2 7

AEs, adverse events.